Carregant...
Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer
Tamoxifen (TAM) resistance is a major challenge in the treatment of estrogen receptor-positive (ER(+)) breast cancer. To date, to the best of our knowledge, there are only a few studies available examining the response of patients with TAM-resistant breast cancer to chemotherapy, and the guidelines...
Guardat en:
| Publicat a: | Int J Oncol |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
D.A. Spandidos
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7050981/ https://ncbi.nlm.nih.gov/pubmed/32319562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.4987 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|